PTCT
$50.14
Revenue | $1176.1Mn |
Net Profits | $866.56Mn |
Net Profit Margins | 73.68% |
PE Ratio | 7.71 |
Ptc Therapeutics, Inc.’s revenue jumped 459.73% since last year same period to $1176.1Mn in the Q1 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 451.71% jump in its revenue since last 3-months.
Ptc Therapeutics, Inc.’s net profit jumped 1046.28% since last year same period to $866.56Mn in the Q1 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 1415.24% jump in its net profits since last 3-months.
Ptc Therapeutics, Inc.’s net profit margin jumped 269.06% since last year same period to 73.68% in the Q1 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 338.39% jump in its net profit margins since last 3-months.
Ptc Therapeutics, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 7.71.
EPS Estimate Current Quarter | -0.71 |
EPS Estimate Current Year | -0.71 |
Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.71 - a -8.46% fall from last quarter’s estimates.
Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.71.
Earning Per Share (EPS) | 10.04 |
Return on Assets (ROA) | 0.24 |
Return on Equity (ROE) | -77.4 |
Ptc Therapeutics, Inc.’s earning per share (EPS) jumped 936.67% since last year same period to 10.04 in the Q1 2025. This indicates that the Ptc Therapeutics, Inc. has generated 936.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ptc Therapeutics, Inc.’s return on assets (ROA) stands at 0.24.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ptc Therapeutics, Inc.’s return on equity (ROE) stands at -77.4.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-05-06 | -0.71 | 10.04 | 1524.11% |